Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Children Ages 2 to <12 Experienced 94.8% Fewer Hereditary Angioedema (HAE) Attacks During Treatment with…